- Extends Atmel | SMART MCU Portfolio Exceeding Industry's Highest Performing ARM® Cortex®-M processor series based MCUs with a 1500 CoreMark Score1
- Delivers Superior Connectivity Options and Unique Memory Architecture Optimized for Real-time Deterministic Code Execution and Low Latency Peripheral Data Access.
HILDEN , Germany , January 12, 2015 /PRNewswire/ --
QIAGEN's circulating tumor DNA test is now CE-IVD marked to assess EGFR mutation status in non-small cell lung cancer (NSCLC) patients based on plasma samples therascreen EGFR RGQ Plasma PCR kit helps physicians to identify patients who could benefit from treatment with IRESSA when tumor tissue sample is not evaluable QIAGEN pioneering the use of liquid biopsy-based companion diagnostics as a less-invasive option to complement surgical biopsies for genomic profiling of cancers QIAGEN (NASDAQ: QGEN; Frankfurt , Prime Standard: QIA) announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.
(NASDAQ:MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced that its
industry-leading technology platform has been adopted by TWi
Biotechnology, Inc .
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.